4月3日周四，诺瓦瓦克斯医药（Novavax，股票代码：NVAX）股价盘中大跌9.78%，引发市场广泛关注。这一显著跌幅与美国食品和药物管理局（FDA）最新的决策延迟密切相关。
据《华尔街日报》报道，FDA未能在规定的最后期限前就诺瓦瓦克斯公司生产的COVID-19疫苗做出关键决定。值得注意的是，这一延迟发生在FDA疫苗主管几天前被撤换之后，这一系列事件可能对公司的疫苗审批进程产生重大影响。
这一消息无疑增加了诺瓦瓦克斯疫苗审批前景的不确定性，市场对此反应强烈。投资者担忧这可能会延迟公司产品的上市时间，从而影响公司的收入预期。在当前竞争激烈的疫苗市场中，任何审批延迟都可能对公司的市场地位造成不利影响。分析人士指出，FDA决策的延迟可能会影响诺瓦瓦克斯的市场策略和财务预期，这解释了为什么股价出现如此明显的下跌。市场将继续密切关注FDA的后续行动及其对诺瓦瓦克斯业务的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.